Galecto an outperform at Oppenheimer on fibrosis assets catalysts

June 21, 2023

in Stocks

Reading Time: 1 min read

Oppenheimer has started Galecto (NASDAQ:GLTO) with an outperform rating saying that the biotech’s fibrosis candidates have upcoming catalysts that could bode well for the company.

The firm has a $12 price target (~323% upside based on Friday’s close).

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Gain access to all our Premium contents.
More than 100+ articles.

Subscribe Now

Buy Article

Unlock this article and gain permanent access to read it.

Unlock Now

Galecto an outperform at Oppenheimer on fibrosis assets catalysts

Related Articles

Stock Market Outlook: 3 Dislocations for Investors to Consider

Will Trump Sell His $Trump Crypto Position? Probably Not, Due to Crash Risk

Biden issues permit for Perpetua’s Idaho antimony and gold mine – Reuters (NASDAQ:PPTA)

Three Reasons Why I’m Bullish on UBER Stock in 2025

Winners and Losers After the Surgeon General’s Alcohol-Cancer Warning

Oil opens new year with strong gains on optimism over economic rebound in China

Photos Show How a Fire Destroyed Secondhand Clothing Market in Ghana

Bitget Launches New Year Futures Perks: Up to 2,000 USDT in Pop Grab and a 50,000 USDT Prize Pool | Currency News | Financial and Business News

Explosive Experts Weigh in on Las Vegas Blast in Front of Trump Hotel

Navigate Site

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?

Galecto an outperform at Oppenheimer on fibrosis assets catalysts

Support authors and subscribe to content

Subscribe

Buy Article

Related Articles

Navigate Site

Follow Us

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?